ESR1 and neoplasm: Gene profiles will very likely expand in use, aiding clinical treatment decisions and leading to increasingly individualized treatment strategies [17], [45], [46] that include clinical characteristics, such as tumor size, grade and lymph node involvement, with the proteins expressed by the tumors (immunohistochemical (IHC) analysis), such as the ER, ki-67, HER2, and molecular profiles.